AZN · story · 3 November
AstraZeneca · 8 headlines from 7 outlets, on 3 November 2026.
Citi, RBC, UBS and others raised targets, Barclays kept Buy, while AlphaValue/Baader downgraded to Reduce.
The story's tone is the average of its headlines' own scores. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Average tone of each outlet's headlines in this story, −10 to +10. Impact = headlines × strength of tone.
Proactive Investors UK is the largest at 9.2, ahead of Yahoo Finance (8.3). Moomoo is the smallest at 0.4.
Source: MarketFrame news analysis
| outlet | Average tone |
|---|---|
| Proactive Investors UK | 9.2 |
| Yahoo Finance | 8.3 |
| Investing.com South Africa | 8.3 |
| TipRanks | 8.3 |
| Benzinga | 7.5 |
| MarketScreener | 6.7 |
| Moomoo | 0.4 |
| Outlet | Headlines | Average tone |
|---|---|---|
| Proactive Investors UK | 1 | +9.2 |
| Yahoo Finance | 1 | +8.3 |
| Investing.com South Africa | 1 | +8.3 |
| TipRanks | 1 | +8.3 |
| Benzinga | 1 | +7.5 |
| MarketScreener | 1 | +6.7 |
| Moomoo | 2 | +0.4 |
One or two headlines is not a lean: read these as how this story was told, not as a verdict on the outlet.
| Tone | What the article reported, and why it scored that way |
|---|---|
| +9.2 | Broker lifts target as pipeline concerns ease. |
| +8.3 | Broker keeps buy view and lifts valuation target. |
| +8.3 | Broker raises target and keeps positive rating. |
| +8.3 | Broker lifts target citing strong results. |
| +8.3 | Broker lifts price target meaningfully. |
| +7.5 | Analyst raises target after results despite timing shift for a drug. |
| −7.5 | Research house cuts recommendation to a sell-type rating. |
| +6.7 | Broker maintains positive recommendation. |
A short, free morning email on how the news treated AstraZeneca: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.